Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: What’s next?

Job Harenberg; Svetlana Marx; Martin Wehling

doi:10.1160/TH12-07-0463

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2012; 108(03): 407-409
DOI: 10.1160/TH12-07-0463

Invited Editorial Focus

Schattauer GmbH

Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: What’s next?

Job Harenberg

¹Department of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht-Karls-University Heidelberg, Germany

,

Svetlana Marx

¹Department of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht-Karls-University Heidelberg, Germany

,

Martin Wehling

¹Department of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht-Karls-University Heidelberg, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 Roskell NS. et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010; 104: 1106-1115.
2 Hart RG. et al. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007; 147: 590-592.
3 Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J Thromb Haemost 2011; 09 (Suppl. 01) 344-351.
4 Ogilvie IM. et al. Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients. Thromb Haemost 2011; 106: 34-44.
5 Wilke T. et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065.
6 Olesen JB. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
7 Gallagher AM. et al. Risks of stroke and mortality associated with suboptimal anticoagulation in at-rial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
8 Ahrens I. et al. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
9 Connolly SJ. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
10 Connolly SJ. et al. Newly identified events in the RELY trial. N Engl J Med 2010; 363: 1875-1876.
11 Patel MR. et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
12 Granger CB. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
13 Mantha S, Ansell J. An Indirect Comparison of Dabigatran, Rivaroxaban and Apixaban for Atrial Fibrillation. Thromb Haemost 2012; 108: 476-484.
14 Glenny AM. et al. Indirect comparisons of competing interventions. Health Technol Assess 2005; 09: 1-134 iii–iv.
15 Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21: 2313-2324.
16 Gage BF. et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005; 118: 612-617.
17 Garcia DA. et al. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010; 104: 1099-1105.
18 Psaty BM. et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. J Am Med Assoc 2003; 289: 2534-2544.
19 Lip GY. et al. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol. 2012 epub ahead of print.
20 Harenberg J. et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Intern Angiol 2012; 31: 330-339.
21 Wells GA. et al. Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation. Available at: http://wwwcadthca/media/pdf/NOAC_Therapeutic_Review_final_reportpdf Accessed July 4th, 2012.
22 Gomez-Outes A. et al. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. Br Med J 2012; 344: e3675.
23 Cohen A. et al. The Efficacy and Safety of Pharmacological Prophylaxis of Venous Thromboembolism Following Elective Knee or Hip Replacement: Systematic Review and Network Meta-Analysis. Clin Appl Thromb Hemost. 2012 epub ahead of print.
24 Fadda V. et al. Network meta-analysis. Results can be summarised in a simple figure. Br Med J 2011; 342: d1555.
25 Banerjee A. et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
26 Kirchhof P. et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost 2011; 106: 1012-1019.